PARIS--(BUSINESS WIRE)--Regulatory News:
The Annual General Meeting of Pixium Vision (Paris:PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, was held in Paris on June 27, 2017 and adopted all the proposed resolutions.
The Annual General Meeting has, in particular, renewed for 3 years the terms of office of Mr Bernard Gilly, Chairman of the Board of Directors, Mr Khalid Ishaque, Chief Executive Officer, and Mr Robert J. W.Ten Hoedt, independent Director.
The Annual General Meeting has also approved the appointments of Sofinnova Partners, who recently step down from its directorship, Mr Timothy J. Haines, whose term of office has expired, and Kreos Capital V (Expert Fund) LTD. as observers for 3 years.
The Board of Directors of Pixium Vision is now composed of the following members:
• Mr Bernard Gilly, Chairman of the Board
• Mr Khalid Ishaque, Chief Executive Officer
• BPIfrance Participations, represented by Mrs Maïlys Ferrère, Director
• BPIfrance Investissement, represented by Mrs Chahra Louafi, Director
• Mr. James Reinstein, Independent Director
• Robert J. W. Ten Hoedt, Independent Director
• Sofinnova Partners, represented by Mr Antoine Papiernik, Observer
• Mr Timothy J. Haines, Observer
• Kreos Capital V (Expert Fund) LTD, represented by Mr Aris Constantidines, Observer
The Board of Directors, meeting at the end of the General Meeting, renewed Mr Bernard Gilly, Chairman of the Board of Directors and Mr Khalid Ishaque, Chief Executive Officer, in their duties.
ABOUT PIXIUM VISION
Pixium Vision’s Mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period.
The company is developing two bionic retinal implant systems. IRIS®II, the company first bionic system, obtained CE mark in July 2016. In parallel, Pixium Vision has recently completed the pre-clinical study phases for PRIMA, a sub-retinal miniaturized wireless photovoltaic implant platform, and is planning to initiate first-in-human trials.
Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Hansen Experimental Physics Laboratory at Stanford University, and Moorfields Eye Hospital in London. The company is EN ISO 13485 certified.
Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Pixium Vision is included in the Euronext CAC All Shares index
Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 "Risk Factors" of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF - AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).
IRIS® is a trademark of Pixium-Vision SA